8-K: Omega Flex Reports Q2 Earnings Decline, Gains CE Mark

Omega Flex, Inc. announced a decrease in net sales and net income for the second quarter and first half of 2026, primarily attributed to market conditions and increased costs, while also achieving CE Mark approval for its MediTrac medical tubing.

Summary

• Omega Flex, Inc. reported a 3.5% decrease in net sales for the first six months of 2026 compared to the same period in 2025, totaling $47,150,000 versus $48,855,000.
• Net sales for the three months ended June 30, 2026, were 5.8% lower than the prior year's second quarter.
• Net income for the first six months of 2026 fell by 38.5% to $4,752,000 from $7,724,000 in the first half of 2025.
• The second quarter of 2026 saw a 35.6% decrease in net income compared to the second quarter of 2025.
• The decline in net income is attributed to higher raw material costs, increased marketing efforts, and product enhancement expenses, partially offset by lower product liability reserves.
• Approximately 30% of the six-month net income decrease and 54% of the three-month decrease were due to higher raw material and marketing costs associated with a new re-engineered flexible gas piping fitting.
• The company launched a re-engineered TracPipe System fitting on July 1, 2026, designed for broader applications and easier installation.
• Omega Flex's MediTrac corrugated medical tubing (CMT) received CE Mark certification in August 2026 as a Class IIa medical device under EU MDR 2017/745.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining sales and net income, despite a positive development in medical tubing certification.

Positives

• Received CE Mark certification for MediTrac corrugated medical tubing (CMT) in August 2026, a significant regulatory approval for medical devices in the European Union.
• MediTrac CMT is a patent-protected, medical-grade product compliant with stringent healthcare codes and standards, including NFPA 99 and Canadian Standard Z7396.1.
• The company believes MediTrac CMT has the potential to serve as a scalable growth platform, leveraging its engineering expertise into new markets.
• Launched a new re-engineered TracPipe System fitting on July 1, 2026, designed to enhance safety, reliability, and ease of installation for residential and commercial construction markets.
• The new fitting supports larger diameter systems (up to two inches) for demanding commercial installations.
• Targeted investments are being made in equipment and facilities to expand capacity, improve operational efficiency, and support geographic growth.
• Higher costs related to the new fitting are expected to be limited in duration and normalize over time.
• Lower product liability reserves and expenses partially offset increased costs.

Negatives

• Net sales decreased by 3.5% ($1,705,000) for the six months ended June 30, 2026, compared to the same period in 2025.
• Net sales for the three months ended June 30, 2026, were 5.8% lower than the prior year's second quarter.
• Net income for the six months ended June 30, 2026, decreased by 38.5% ($2,972,000) compared to the first half of 2025.
• Net income for the three months ended June 30, 2026, was 35.6% lower than the same period in 2025.
• Higher raw material costs, including inbound transportation and tariffs, significantly impacted net income.
• Increased marketing efforts and product enhancement/certification expenses contributed to the decline in profitability.
• The overall market for the company's products continues to be suppressed, partly due to a decline in housing starts.

Risks

• Market suppression due to factors like declining housing starts could continue to impact sales unit volumes.
• Higher raw material costs, including inbound transportation and tariffs, are expected to continue as the company procures inventory and markets the new fitting.
• The company's financial performance is subject to risks and uncertainties detailed in its Form 10-K for the year ended December 31, 2025, and subsequent SEC filings.
• Forward-looking statements are subject to inherent risks, uncertainties, and changes in circumstances that are difficult to predict and may cause actual results to differ materially.

Future Outlook

The company believes that the higher costs associated with raw materials and marketing for the new fitting will be limited in duration and will normalize over time. Targeted investments are being made to expand capacity, enhance operational efficiency, and support geographic growth.

Management Comments

• "The decrease in net sales was mainly due to lower sales unit volumes as the overall market continued to be suppressed because of, among other factors, a decline in housing starts."
• "The decrease in net income was mainly due to higher raw material costs (including inbound transportation costs and tariffs); marketing efforts; and product enhancement and certification related expenses."
• "However, the Company believes that these higher costs will be limited in duration and will normalize over time."
• "We are extremely proud to achieve CE mark certification for MediTrac CMT, said Dean W. Rivest, Chief Executive Officer of Omega Flex, Inc. and President and Chief Executive Officer of Flex-Trac, Inc."
• "Combined with the ISO 13485:2016 quality management system certification, this milestone highlights our dedication to producing safe, reliable, and innovative medical gas tubing solutions for healthcare systems around the world."
• "We believe MediTrac CMT has the potential to serve as a scalable growth platform that extends our engineering expertise into new geographic regions and markets while leveraging our established manufacturing and quality systems."

Industry Context

StockSavvy.ai notes that the decline in housing starts is a significant headwind for companies in the construction materials sector, impacting demand for products like flexible gas piping. The CE Mark approval for MediTrac CMT positions Omega Flex in the growing medical device market, a sector often less sensitive to construction cycles.

Stakeholder Impact

• Shareholders may be impacted by the decrease in net income and earnings per share.
• Customers in the construction sector may benefit from the new, re-engineered flexible gas piping fitting.
• Healthcare facilities globally may benefit from the CE-certified MediTrac CMT for medical gas distribution.

Next Steps

• Continue to procure raw materials to achieve targeted inventory levels for the new fitting.
• Continue to market the new re-engineered flexible gas piping fitting.
• Leverage MediTrac CMT as a scalable growth platform into new geographic regions and markets.
• Continue targeted investments in equipment and facilities to expand capacity and enhance operational efficiency.

Key Dates

Recommendation

The filing indicates a worsening financial performance with declining sales and net income, driven by market conditions and increased costs. While the CE Mark approval for MediTrac CMT is a positive development and a potential future growth driver, the immediate financial results and ongoing cost pressures suggest a cautious approach. Therefore, a 'hold' recommendation is appropriate pending signs of recovery in sales and profitability or further clarity on the growth trajectory of the medical tubing segment.

Keywords

flexible metal hose, gas piping, medical tubing, CE Mark, TracPipe, MediTrac, construction market, medical device